GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

One in 8 adults say they are currently taking a GLP-1 drug for weight loss, diabetes, or another condition, KFF poll finds

About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a KFF Health Tracking Poll finds.

November 21, 2025

Vol.51 No.43

Cancer Policy

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

FDA announced six additional awardees under the Commissioner’s National Priority Voucher pilot program, which aims to accelerate review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, Oct. 24, June 20, 2025).

White House makes deal with Eli Lilly, Novo Nordisk to lower weight loss drug prices and begin Medicare coverage

The White House Nov. 6 announced a deal with drugmakers Eli Lilly and Co. and Novo Nordisk to expand coverage and reduce prices for their obesity treatments, Zepbound and Wegovy.

November 07, 2025

Vol.51 No.41

By Jacquelyn Cobb

Clinical Trials & Tribulations

How GLP-1RA drugs are reshaping patient physiology and the future of oncology

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?

CRC patients with cannabis use disorder may have higher odds of death within five years of diagnosis
Observational study suggests that clinicians should be cautious when recommending cannabis to manage cancer symptoms

Cannabis use disorder is associated with a dramatically increased odds of death within five years of diagnosis in people with colorectal cancer, a recent observational study found.

Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer.

June 06, 2025

Vol.51 No.22

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

YOU MAY BE INTERESTED IN

One in 8 adults say they are currently taking a GLP-1 drug for weight loss, diabetes, or another condition, KFF poll finds

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

White House makes deal with Eli Lilly, Novo Nordisk to lower weight loss drug prices and begin Medicare coverage

How GLP-1RA drugs are reshaping patient physiology and the future of oncology

CRC patients with cannabis use disorder may have higher odds of death within five years of diagnosis
Observational study suggests that clinicians should be cautious when recommending cannabis to manage cancer symptoms

Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find

Renew today!

Subscriber content

Never miss an issue!

Login

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

YOU MAY BE INTERESTED IN

One in 8 adults say they are currently taking a GLP-1 drug for weight loss, diabetes, or another condition, KFF poll finds

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

White House makes deal with Eli Lilly, Novo Nordisk to lower weight loss drug prices and begin Medicare coverage

How GLP-1RA drugs are reshaping patient physiology and the future of oncology

CRC patients with cannabis use disorder may have higher odds of death within five years of diagnosisObservational study suggests that clinicians should be cautious when recommending cannabis to manage cancer symptoms

Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find

Never miss an issue!

Login

CRC patients with cannabis use disorder may have higher odds of death within five years of diagnosis
Observational study suggests that clinicians should be cautious when recommending cannabis to manage cancer symptoms